Multiple sclerosis · Minneapolis

Multiple sclerosis clinical trials in Minneapolis

2 recruiting multiple sclerosis studies within range of Minneapolis. Click any trial for full eligibility criteria and contact info.

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

NCT04047628 · Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

Recruiting

This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).

PhasePhase 3

TypeInterventional

Age18 Years – 55 Years

WherePalo Alto, California, United States + 21 more

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)

▾Tap for detailsClick for full details — eligibility, all locations, contacts

22 sitesApply on CT.gov

Apply on CT.gov Open full pageClinicalTrials.gov ↗

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896 · Scleroderma, Diffuse

Recruiting

The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.

PhasePhase 2

TypeInterventional

Age18 Years – 70 Years

WhereLos Angeles, California, United States + 91 more

SponsorNovartis Pharmaceuticals

▾Tap for detailsClick for full details — eligibility, all locations, contacts

92 sitesApply

Apply Open full pageClinicalTrials.gov ↗

← All multiple sclerosis trials (nationwide)